Global Primary Immunodeficiency Drug Market Growth 2025-2031

The global Primary Immunodeficiency Drug market size is predicted to grow from US$ 8032 million in 2025 to US$ 11880 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.

Drugs for the treatment of primary immunodeficiency diseases

Based on disease or condition, the antibody deficiency segment held the largest share in the overall PIDD market owing to the increasing number of patients diagnosed with common variable immunodeficiency and selective IgA deficiency. In terms of treatment methods, immunoglobulin replacement therapy occupies the largest share of the global PID market, and is an effective, safe and preferred therapy for the treatment of primary immunodeficiency.

LP Information, Inc. (LPI) ' newest research report, the “Primary Immunodeficiency Drug Industry Forecast” looks at past sales and reviews total world Primary Immunodeficiency Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Immunodeficiency Drug sales for 2025 through 2031. With Primary Immunodeficiency Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Immunodeficiency Drug industry.

This Insight Report provides a comprehensive analysis of the global Primary Immunodeficiency Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Immunodeficiency Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Immunodeficiency Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Immunodeficiency Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Immunodeficiency Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Immunodeficiency Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Immunoglobulin
Antibiotic
Stem Cell
Other

Segmentation by Application:
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disease
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Primary Immunodeficiency Drug market?

What factors are driving Primary Immunodeficiency Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Primary Immunodeficiency Drug market opportunities vary by end market size?

How does Primary Immunodeficiency Drug break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.